Aripiprazole Sandoz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0029 
Minor change in labelling or package leaflet not 
11/12/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0027 
A.5.b - Administrative change - Change in the name 
14/09/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
IB/0026 
B.II.z - Quality change - Finished product - Other 
22/12/2022 
n/a 
variation 
IA/0025 
B.III.1.a.2 - Submission of a new/updated or 
31/10/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/09/2022 
12/10/2022 
SmPC and PL 
To update SmPC section 4.8 by adding "blood prolactin 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0022/G 
This was an application for a group of variations. 
13/06/2022 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IA/0021 
B.I.b.2.a - Change in test procedure for AS or 
17/03/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0020 
A.7 - Administrative change - Deletion of 
12/11/2021 
n/a 
decreased" in the tabulated lists of adverse reactions. 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
IB/0018/G 
This was an application for a group of variations. 
26/10/2021 
12/10/2022 
SmPC and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019/G 
This was an application for a group of variations. 
20/10/2021 
n/a 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IA/0017 
A.7 - Administrative change - Deletion of 
22/07/2021 
n/a 
manufacturing sites 
PSUSA/234/2
Periodic Safety Update EU Single assessment - 
11/02/2021 
n/a 
PRAC Recommendation - maintenance 
02007 
aripiprazole 
IA/0016 
B.I.b.2.a - Change in test procedure for AS or 
23/10/2020 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
R/0014 
Renewal of the marketing authorisation. 
30/04/2020 
26/06/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Aripiprazole Sandoz in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
PSUSA/234/2
Periodic Safety Update EU Single assessment - 
27/02/2020 
28/04/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01907 
aripiprazole 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/234/201907. 
IA/0013 
B.III.1.a.2 - Submission of a new/updated or 
12/12/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/234/2
Periodic Safety Update EU Single assessment - 
28/02/2019 
29/04/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01807 
aripiprazole 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/234/201807. 
IB/0011 
B.II.b.5.c - Change to in-process tests or limits 
30/10/2018 
n/a 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/02/2018 
16/03/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
PSUSA/234/2
Periodic Safety Update EU Single assessment - 
08/02/2018 
n/a 
PRAC Recommendation - maintenance 
01707 
aripiprazole 
IAIN/0007 
B.III.1.a.1 - Submission of a new/updated or 
13/09/2017 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
11/04/2017 
16/03/2018 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/234/2
Periodic Safety Update EU Single assessment - 
09/02/2017 
n/a 
PRAC Recommendation - maintenance 
01607 
aripiprazole 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/12/2016 
16/02/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/07/2016 
16/02/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0001/G 
This was an application for a group of variations. 
17/03/2016 
16/02/2017 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
